PHARMACOLOGY UPDATE

Infliximab-dyyb for Injection (Inflectra)

Name: Relias Media
Price range: $

May 15, 2016

Infliximab-dyyb offers another, possibly less expensive, option for treatment of a number of autoimmune conditions.

Issue Date: May 15, 2016

Table of Contents

Internal Medicine Alert’s Editor Stephen Brunton, MD, is a retained consultant for Abbott, Actavis, AstraZeneca, Becton Dickinson, Boehringer Ingelheim, Cempra, Exact Sciences, Janssen, Lilly, Mylan, Novo Nordisk, and Teva; he serves on the speakers bureau of AstraZeneca, Boehringer Ingelheim, Janssen, Lilly, Novo Nordisk, and Teva. Contributing Editor Louis Kuritzky, MD, is a retained consultant for AbbVie, Allergan, AstraZeneca, Janssen, Lilly, Lundbeck, Medscape, Novo Nordisk, and Sanofi Aventis; he serves on the speakers bureau of Lilly and Lundbeck. Peer Reviewer Gerald Roberts, MD; Executive Editor Leslie Coplin; and Associate Managing Editor Jonathan Springston report no financial relationships relevant to this field of study.

Subscription Publication Books & Study Guides Group & Site Licenses State CME/CE Requirements